Paraproteinemias clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
open to eligible people ages 18 years and up
The goal of this clinical trial is to evaluate the safety, tolerability, and recommended Phase 2 Dose (RP2D) of KLN-1010 in patients with relapsed or refractory multiple myeloma.
at UCSF
Our lead scientists for Paraproteinemias research studies include Jodi Lipof, MD.
Last updated: